 In this video, we'll talk about a penny stock that I think is ready for exponential growth. We'll go through this stock, what I think about it, why my analysis on the stock, some of the research on the stock, and some of the information. I've got to say that I'm not a financial advisor, I'm a business teacher in my daily life, but I'm by no means an expert on the stock market. So let's go into this penny stock that I think's ready for growth and get right into the information for you. If you leave a like at some point in the video, that'd be brilliant. It really helps out this small channel to grow and we have been growing a lot. So thank you for the support. So Iconvest could buy this stock as well. So that'd be interesting because this fits in with their portfolio in terms of the sorts of stocks they look for. So it could be a potential buy from Iconvest. So if Iconvest do buy that, it'll help it as being a catalyst as well. But that's only a possibility, that's a speculation. What the stock is. So it's called BioNANA genomics, okay? And it's an interesting stock. And I'm not going to give a scientific analysis of this because I'm a business person. I'm not a scientist. So I'm looking at this from a business perspective. But I think that what they're producing here has a need, okay? Definitely does have a need. It's got a demand for the sort of products that they're providing. And it seems like a very good business overall, what they're trying to do. So they're creating a market leader in digital cytogenetics. I apologize if I butcher any of the words, okay? Product solutions with the Sapphire system and CLIA diagnostic services via the lineage business and Sapphire, okay? So let's go into the information. So what is it that they're looking at doing or partly doing as part of their processes and their research and development? So cytogenetics is the current paradigm in testing for SVs. So it's in terms of the detections of this here. And what does it test for? It can test for diseases caused by large gene genomic aberrations, also known as structural abnormalities, okay? And structural abnormalities include translocations, insertions, deletions, okay? Another rearrangement of genomic information, okay? So this is a product that's going to be in demand. There's a need for this sort of product, this health product. But before we get into some further information about this stock, if you can like the video and also subscribe to the channel. We just want to see if we can hit 2,000 subscribers by New Year. I'll thank everybody for all the support that's been offered on this channel. And it's really helped me out. Like we've grown so fast so quickly. So, and that's only down to everybody that's watching the videos and liking the videos. So thank you for everybody who keeps supporting every video, it's fantastic. And to any new people, welcome to the channel. We cover a range of different stocks. I'm gonna get right back into the information though, just to respect your time. I won't waffle on about subscribers and likes and all that. So let's go back into it. So digital cytogenetics with this, they've got a certain software for detecting, well, they've got a certain process, should I say, for detecting SVs recommended by medical guidelines. And ultimately, some of these healthcare products, what they suffer from sometimes is in terms of a process that is too difficult or a process that isn't easy. Whereas this particular product has a process that is step-by-step stage and it's quite easy. Okay, so you've got the sample. So you take the sample, whether it be, tissue, biopsies, burn, marrow, blood, and then you get the DNA extraction. You load the sample into the systems that they've got. They're, I believe that this is patented. And then you get your sample analysed to see what it says, what's the information. So it's a very simple process of using this particular healthcare product. And this is interest, this is where it gets interesting to me as an investor is what is the potential market? What are we talking about in terms of money? So we estimate the market to be $2.6 billion to $3.8 billion, okay? So this market has got, so it's a large market for a penny stock, you know. Think about the fact that it's a penny stock. Think about the fact that this area is potentially a lot of barriers to entry because you need to put loads of research and development costs into producing products like this. And there's a lot of barriers to entry with that. Now, they've already produced something here that can meet that total addressable market. And even if they get a small portion of that, that is a very, very good company in terms of actually revenue, okay? And it's saying here, 2,500 cytogenetic labs worldwide, okay? Estimated revenue of $0.5 billion to $0.6 billion, estimating annual reoccurring revenues, or $0.2 billion to $0.4 billion, that's really important there. So it's not just one-off revenues that they're getting, they're getting some reoccurring revenue and that is really powerful for a business because that adds to the sustainability of the business there. Then the discovery research here is quickly growing. 1.4 billion to 1.8 billion estimated revenues. And again here, 0.5 to 1.1 billion estimated reoccurring annual revenues. So there's a lot of potential here for growth for this company in terms of the revenues that it can generate. So we've got a snapshot of 2019 in millions here. So at the minute, well in 2019 shall we say from what I found from a previous presentation because sometimes I like to look at the previous presentations and the investor information from previous years so we can see how it's developed over time rather than just looking at anything that's the updated information. I like to look at some of the past information as well, particularly with some revenues. Although the revenues here are not a true reflection of what it can do in the future. I think certainly in the future it can absolutely explode on revenue compared to what this is at the moment. So revenue here, you've got the standalone of 10 million there, then you've got 7.5 and in terms of both of them together, I think in 17.6 million in revenue and the cost of the revenue was 10.2 million. So there's a lot of revenue there and that was in 2019, 17.6 million in a year. That's a really good revenue. They've also got here what seems to be an experienced management team as well. So they've got people involved in the company. Here you've got a CEO who's got a PhD and he's been involved in loads of different companies. Got a chief operating officer again, involved in quite a few companies that are quite good there as well in terms of he's had that experience. A chief financial officer that's worked at Tesla which is very interesting because having that individual working from Tesla, chief financial officer, it's good that they've got someone experienced there to maintain the finances and then you've got the chief medical officer with a PhD there as well. And then the load of a wide range of board of directors as well. So it seems that they've got an experienced team here which is really important for a growth of a company. So what is the benefit? So it's got good total addressable market for a penny stock. There's a market out there for this product. The second point is that there's high barriers to entry. So there's going to be needed to be a lot of market research, a lot of research and development for any competitors to compete with what they're doing. So there is potential high barriers which means that ultimately they could maybe take a large chunk of that total addressable market because there's less competition involved there because of the high barriers to entry. Then you've got revenue growth in terms of, you can see historically it's had some revenue growth and that's going to continue. The products actually available as well. You can see a lot of these penny stocks and actually they don't have a product yet. So the fact that they've got a product is really important there and they've got a product available there. It's also strong leadership as well in terms of they've got experienced leadership, people with a wide range of skill sets, very experienced, very credible, prominent people which is great to see. Now just looking at the price, it's currently set at $1.33 USD. I would buy at this price, okay. Don't just automatically be like I'll buy. I think because what I've seen here is that that is just too good. The massive total addressable market, good revenue, good leadership team, serious, credible company, serious even though it's a penny stock it feels like an incredibly serious company, right. And I would certainly buy this at $1.33. I put in a small, I put, well I say, I put in a small position of my overall portfolio because obviously we don't like, we like to diversify. It's important that we only put a certain amount on each stock and diversify. Now interestingly enough, it said the stock price forecast for this is in 12 months, the four analysts have got this on the low end of 75 cent, the medium at $1.38 and the high of $2.00. Now that is what they're saying there but we've noticed that there's a lot of stocks out there that have blown past analyst expectations and I think this could be potentially one of them here. So if you go into buying to this stock I would try and get it at any point below $2.00 but again, this could blow past analyst expectations here. So bear that in mind but certainly this is one of the stocks to look at here. Yeah, so I would predict that there's going to be some more analysts that look at this stock because this stock has actually got a lot of investor sentiment. There's a lot of people making videos on it. There's a lot of people talking about the stock in investor groups which starts to become more well known and I think that actually looking at the fundamentals of the stock and any favor announcements they come out with, the analysts may have a relook at this and they may upgrade their pricing here because it does seem fairly low to me. I would say this stock is going to be easily worth three to $4.00 in the next couple of weeks actually. $3.00 in the next couple of weeks is what I'm saying. Well, it's going to hit $3.00 in a couple of weeks. Okay, I really do think that. I think it's a really good company but by the way, obviously don't take my word for it. I'm not a financial advisor. You do your own research. I'm just going off my own analysis and use that as a package of your information. Anyways, if you found this video useful at all at any point then do leave the video a like and subscribe to the channel if you're new. People always ask you, how can we support you? Are you going to start a Patreon or anything like that? I'm not going to do that yet. I don't think I'm not at that level to justify doing that. So if you want to support us in any way, all they ask is in it's free. I'm not selling any courses, it's free. Just like the video and that's all they ask really. So thanks for watching and I'll see everybody in the next video.